AR096882A1 - Metanosulfonato de 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona - Google Patents

Metanosulfonato de 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona

Info

Publication number
AR096882A1
AR096882A1 ARP140102566A ARP140102566A AR096882A1 AR 096882 A1 AR096882 A1 AR 096882A1 AR P140102566 A ARP140102566 A AR P140102566A AR P140102566 A ARP140102566 A AR P140102566A AR 096882 A1 AR096882 A1 AR 096882A1
Authority
AR
Argentina
Prior art keywords
dihydro
oxo
methylene
thyzolidine
morpholinylmetil
Prior art date
Application number
ARP140102566A
Other languages
English (en)
Inventor
Guidotti Jrme
Le Flohic Alexandre
Letellier Philippe
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR096882A1 publication Critical patent/AR096882A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Metanosulfonato de 3-[(3-{[4-(4-morfolinilmetil)-1H-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1H-indol-5-il)metil]-1,3-tiazolidina-2,4-diona de fórmula (1) en la que la notación designada como (a) significa que el doble enlace tiene configuración Z ó E. Reivindicación 2: Compuesto según la reivindicación 1 que es el isómero Z del metanosulfonato de 3-[(3-{[4-(4-morfolinilmetil)-1H-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1H-indol-5-il)metil]-1,3-tiazolidina-2,4-diona.
ARP140102566A 2013-07-12 2014-07-11 Metanosulfonato de 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona AR096882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1356870A FR3008411B1 (fr) 2013-07-12 2013-07-12 Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent

Publications (1)

Publication Number Publication Date
AR096882A1 true AR096882A1 (es) 2016-02-03

Family

ID=50424327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102566A AR096882A1 (es) 2013-07-12 2014-07-11 Metanosulfonato de 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona

Country Status (47)

Country Link
US (2) US9925195B2 (es)
EP (1) EP3019497B1 (es)
JP (1) JP6532459B2 (es)
KR (2) KR20160030399A (es)
CN (1) CN105377843B (es)
AP (1) AP2016008976A0 (es)
AR (1) AR096882A1 (es)
AU (1) AU2014289059B2 (es)
CA (1) CA2916380C (es)
CL (1) CL2016000013A1 (es)
CR (1) CR20160012A (es)
CU (1) CU20160005A7 (es)
CY (1) CY1119259T1 (es)
DK (1) DK3019497T3 (es)
DO (1) DOP2016000005A (es)
EA (1) EA031526B1 (es)
ES (1) ES2632570T3 (es)
FR (1) FR3008411B1 (es)
GE (1) GEP201706712B (es)
GT (1) GT201600004A (es)
HK (2) HK1222172A1 (es)
HR (1) HRP20171060T1 (es)
HU (1) HUE032568T2 (es)
IL (1) IL243526B (es)
JO (1) JO3292B1 (es)
LT (1) LT3019497T (es)
MA (1) MA38759B1 (es)
MD (1) MD4507C1 (es)
ME (1) ME02735B (es)
MX (1) MX360291B (es)
MY (1) MY183197A (es)
NI (1) NI201600009A (es)
NZ (1) NZ715841A (es)
PE (1) PE20160079A1 (es)
PH (1) PH12016500017A1 (es)
PL (1) PL3019497T3 (es)
PT (1) PT3019497T (es)
RS (1) RS55945B1 (es)
RU (1) RU2680826C9 (es)
SA (1) SA516370388B1 (es)
SG (1) SG11201510570YA (es)
SI (1) SI3019497T1 (es)
TN (1) TN2015000566A1 (es)
TW (2) TWI554510B (es)
UA (1) UA114041C2 (es)
UY (1) UY35629A (es)
WO (1) WO2015004395A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245270B2 (en) * 2013-07-12 2019-04-02 Les Laboratoires Servier Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00415B (me) * 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
EP1328519B1 (en) * 2000-10-17 2005-09-07 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
DE60205776T2 (de) * 2001-12-27 2006-06-14 Theravance Inc Indolinon-derivative als protein-kinasehemmer
EP1680401A2 (en) * 2003-10-24 2006-07-19 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
ES2391575T3 (es) * 2005-12-05 2012-11-27 Xenoport, Inc. Mesilato de profármaco de Levodopa, sus composiciones y sus usos
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PH12016500017B1 (en) 2016-04-18
JP6532459B2 (ja) 2019-06-19
US20160151378A1 (en) 2016-06-02
AU2014289059A1 (en) 2016-02-04
EP3019497A1 (fr) 2016-05-18
CU20160005A7 (es) 2016-05-30
RU2680826C2 (ru) 2019-02-28
HK1222655A1 (zh) 2017-07-07
CR20160012A (es) 2016-02-08
EA031526B1 (ru) 2019-01-31
TN2015000566A1 (fr) 2017-04-06
JP2016523953A (ja) 2016-08-12
UY35629A (es) 2015-01-30
GT201600004A (es) 2018-09-28
DK3019497T3 (en) 2017-08-07
MD4507B1 (ro) 2017-08-31
MD20160003A2 (ro) 2016-06-30
HRP20171060T1 (hr) 2017-10-06
FR3008411B1 (fr) 2015-07-03
RS55945B1 (sr) 2017-09-29
MA38759A1 (fr) 2018-01-31
CL2016000013A1 (es) 2016-08-12
SA516370388B1 (ar) 2017-12-14
LT3019497T (lt) 2017-05-25
AP2016008976A0 (en) 2016-01-31
EA201600101A1 (ru) 2016-06-30
SI3019497T1 (sl) 2017-07-31
CA2916380C (fr) 2017-11-21
MX2016000332A (es) 2016-05-09
US9925195B2 (en) 2018-03-27
DOP2016000005A (es) 2016-12-15
MD4507C1 (ro) 2018-03-31
CN105377843B (zh) 2019-03-05
MX360291B (es) 2018-10-29
MA38759B1 (fr) 2018-09-28
ES2632570T3 (es) 2017-09-14
KR20160030399A (ko) 2016-03-17
UA114041C2 (xx) 2017-04-10
IL243526B (en) 2019-09-26
JO3292B1 (ar) 2018-09-16
CN105377843A (zh) 2016-03-02
TW201504236A (zh) 2015-02-01
PT3019497T (pt) 2017-05-15
WO2015004395A1 (fr) 2015-01-15
NI201600009A (es) 2016-02-11
TW201630906A (zh) 2016-09-01
PL3019497T3 (pl) 2017-09-29
CA2916380A1 (fr) 2015-01-15
HK1222172A1 (zh) 2017-06-23
FR3008411A1 (fr) 2015-01-16
RU2680826C9 (ru) 2019-03-01
MY183197A (en) 2021-02-18
CY1119259T1 (el) 2018-02-14
EP3019497B1 (fr) 2017-04-12
TWI554510B (zh) 2016-10-21
NZ715841A (en) 2019-04-26
AU2014289059B2 (en) 2017-05-25
ME02735B (me) 2017-10-20
IL243526A0 (en) 2016-02-29
PE20160079A1 (es) 2016-02-06
SG11201510570YA (en) 2016-01-28
RU2016104642A (ru) 2017-08-17
PH12016500017A1 (en) 2016-04-18
HUE032568T2 (hu) 2017-09-28
GEP201706712B (en) 2017-07-25
US20180207171A1 (en) 2018-07-26
KR20180028554A (ko) 2018-03-16

Similar Documents

Publication Publication Date Title
AR119765A1 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CY1121155T1 (el) Ενωσεις ν-ετεροαρυλιου υποκατεστημενες με ν-αζασπιροκυκλοαλκανιο και συνθεσεις για την αναστολη της δραστηριοτητας της shp2
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
UY36480A (es) Uso de compuestos de picolinamida como fungicidas
CY1118950T1 (el) Νεα παραγωγα πυραζολιου
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
GT201200230A (es) Inhibidores del virus de la hepatitis c
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY34393A (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
BR112016006076A2 (pt) compostos de picolinamida macrocíclica com atividade fungicida
CR20150271A (es) Peptidos como agonistas de oxitocina
CL2017000152A1 (es) Derivados de isoindolinona
CR20150382A (es) Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3,4-dihidropirimidin-1-(2h)-carboxilato
CR20170005A (es) Derivados de insoindolina
CR20160557A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
CL2012000278A1 (es) Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados.
CR20160448A (es) Nuevos derivados de piridina
CL2017000151A1 (es) Derivados de piridona
ES2571577T3 (es) Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2
BR112013021882A2 (pt) síntese de compostos orgânicos
EA201692139A1 (ru) Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
AR096882A1 (es) Metanosulfonato de 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona
CR20140564A (es) Derivados de pirimidinona como agentes antimaláricos
ES2570976T3 (es) Derivado de 2,4-diaminopirimidina bicíclico condensado como inhibidor dual de ALK y FAK

Legal Events

Date Code Title Description
FB Suspension of granting procedure